Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

This trial is studying pembrolizumab (an immunotherapy drug) combined with chemotherapy and image-guided surgery for people diagnosed with malignant pleural mesothelioma (MPM), a rare cancer of the lining of the lungs usually associated with asbestos exposure. **You may be eligible if...** - You have been diagnosed with malignant pleural mesothelioma (MPM) - You have measurable disease on imaging - You are 18 years or older and in reasonable health - You are willing to provide a tumor biopsy sample **You may NOT be eligible if...** - You have already received prior immunotherapy or chemotherapy for this cancer - You have autoimmune conditions that could be worsened by immunotherapy - You are on long-term immunosuppressive medications - You are pregnant or breastfeeding - You have active infections including HIV or Hepatitis B/C Talk to your doctor to see if this trial is right for you.